SG11201503982XA - Substituted reverse pyrimidine bmi-1 inhibitors - Google Patents
Substituted reverse pyrimidine bmi-1 inhibitorsInfo
- Publication number
- SG11201503982XA SG11201503982XA SG11201503982XA SG11201503982XA SG11201503982XA SG 11201503982X A SG11201503982X A SG 11201503982XA SG 11201503982X A SG11201503982X A SG 11201503982XA SG 11201503982X A SG11201503982X A SG 11201503982XA SG 11201503982X A SG11201503982X A SG 11201503982XA
- Authority
- SG
- Singapore
- Prior art keywords
- inhibitors
- bmi
- substituted reverse
- reverse pyrimidine
- substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hematology (AREA)
- Oncology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261728907P | 2012-11-21 | 2012-11-21 | |
| PCT/US2013/071132 WO2014081906A2 (en) | 2012-11-21 | 2013-11-21 | Substituted reverse pyrimidine bmi-1 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201503982XA true SG11201503982XA (en) | 2015-06-29 |
Family
ID=50776672
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201600149VA SG10201600149VA (en) | 2012-11-21 | 2013-11-21 | Substituted reverse pyrimidine bmi-1 inhibitors |
| SG11201503982XA SG11201503982XA (en) | 2012-11-21 | 2013-11-21 | Substituted reverse pyrimidine bmi-1 inhibitors |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201600149VA SG10201600149VA (en) | 2012-11-21 | 2013-11-21 | Substituted reverse pyrimidine bmi-1 inhibitors |
Country Status (32)
| Country | Link |
|---|---|
| US (3) | US10428050B2 (en) |
| EP (1) | EP2922828B1 (en) |
| JP (3) | JP6412503B2 (en) |
| KR (4) | KR102455889B1 (en) |
| CN (2) | CN104918919A (en) |
| AR (1) | AR093579A1 (en) |
| AU (1) | AU2013348009C1 (en) |
| BR (1) | BR112015011760B1 (en) |
| CA (1) | CA2892045C (en) |
| CL (1) | CL2015001377A1 (en) |
| CR (1) | CR20150294A (en) |
| CU (1) | CU24387B1 (en) |
| DK (1) | DK2922828T3 (en) |
| EA (2) | EA035349B1 (en) |
| EC (1) | ECSP15019948A (en) |
| ES (1) | ES2821529T3 (en) |
| HK (1) | HK1215032A1 (en) |
| IL (2) | IL238871B (en) |
| MA (1) | MA38208B1 (en) |
| MX (2) | MX2015006469A (en) |
| NI (1) | NI201500072A (en) |
| NZ (2) | NZ708909A (en) |
| PE (1) | PE20151413A1 (en) |
| PH (1) | PH12015501130A1 (en) |
| PL (1) | PL2922828T3 (en) |
| PT (1) | PT2922828T (en) |
| SA (1) | SA517381847B1 (en) |
| SG (2) | SG10201600149VA (en) |
| TW (1) | TWI623531B (en) |
| UA (1) | UA118094C2 (en) |
| WO (1) | WO2014081906A2 (en) |
| ZA (1) | ZA201503642B (en) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI623531B (en) * | 2012-11-21 | 2018-05-11 | Ｐｔｃ治療公司 | Substituted reverse pyrimidine bmi-1 inhibitors |
| WO2015003360A2 (en) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| WO2015003355A2 (en) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| US9579324B2 (en) | 2013-07-11 | 2017-02-28 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
| EP3019480B1 (en) * | 2013-07-11 | 2020-05-06 | Agios Pharmaceuticals, Inc. | 2,4- or 4,6-diaminopyrimidine compounds as idh2 mutants inhibitors for the treatment of cancer |
| KR102232595B1 (en) | 2013-08-30 | 2021-03-26 | 피티씨 테라퓨틱스, 인크. | Substituted pyrimidine bmi-1 inhibitors |
| WO2015076800A1 (en) | 2013-11-21 | 2015-05-28 | Ptc Therapeutics, Inc. | Substituted pyridine and pyrazine bmi-1 inhibitors |
| EP3335126A4 (en) | 2015-08-11 | 2019-05-01 | Cognoa, Inc. | Methods and apparatus to determine developmental progress with artificial intelligence and user input |
| US10851082B2 (en) | 2015-10-28 | 2020-12-01 | Northwestern University | Substituted aromatic n-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (MNK1) and 2 (MNK2) |
| US11972336B2 (en) | 2015-12-18 | 2024-04-30 | Cognoa, Inc. | Machine learning platform and system for data analysis |
| CN108602775B (en) * | 2016-01-14 | 2022-04-29 | 贝思以色列女会吏医学中心公司 | Mast cell modulators and uses thereof |
| EP3580700A4 (en) | 2017-02-09 | 2020-11-18 | Cognoa, Inc. | Platform and system for digital personalized medicine |
| EP3664803A4 (en) | 2017-08-01 | 2021-05-05 | PTC Therapeutics, Inc. | Dhodh inhibitor for use in treating hematologic cancers |
| EP3564235A1 (en) * | 2018-05-03 | 2019-11-06 | Northwestern University | Substituted aromatic n-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (mnk1) and 2 (mnk2) |
| MX2021001870A (en) * | 2018-08-17 | 2021-07-15 | Ptc Therapeutics Inc | Method for treating pancreatic cancer. |
| CN109988172B (en) * | 2019-01-10 | 2020-09-29 | 石家庄学院 | Synthesis method of pyrazolo [1,5-A ] pyrimidine heterocyclic compound and derivative |
| WO2020150326A1 (en) * | 2019-01-15 | 2020-07-23 | Ptc Therapeutics, Inc. | Method for treating an acute myeloid leukemia |
| CA3131249A1 (en) * | 2019-02-28 | 2020-09-03 | Ptc Therapeutics, Inc. | 5-fluoro-2-(6fluoro-2-methyl-1h-benzo(d)imidazol-1-yl)-n4-(4-(trifluoromethyl)phenyl)pyrimidine-4,6-diamine dor treating a multiple myeloma |
| MX2021010906A (en) * | 2019-03-11 | 2021-10-01 | Ptc Therapeutics Inc | Compound form having enhanced bioavailability and formulations thereof. |
| CA3134521A1 (en) | 2019-03-22 | 2020-10-01 | Cognoa, Inc. | Personalized digital therapy methods and devices |
| JP2022519930A (en) * | 2019-03-27 | 2022-03-25 | ピーティーシー セラピューティクス， インコーポレイテッド | A useful combination for how to treat sarcoma |
| KR20210125558A (en) * | 2019-04-02 | 2021-10-18 | 하이노바 파마슈티컬스 인코포레이티드 | Aromatic amine compounds and their use in the preparation of AR and BRD4 dual inhibitors and modulators |
Family Cites Families (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH593266A5 (en) | 1973-09-20 | 1977-11-30 | Delalande Sa | |
| DE69530989T2 (en) | 1994-08-13 | 2004-05-19 | Yuhan Corp. | NEW PYRIMID DERIVATIVES AND METHOD FOR THEIR PRODUCTION |
| IN188411B (en) | 1997-03-27 | 2002-09-21 | Yuhan Corp | |
| KR100272471B1 (en) | 1998-11-17 | 2000-11-15 | 김선진 | Novel pyrimidine derivatives and processes for the preparation thereof |
| GB9905075D0 (en) * | 1999-03-06 | 1999-04-28 | Zeneca Ltd | Chemical compounds |
| ATE253915T1 (en) | 1999-06-30 | 2003-11-15 | Merck & Co Inc | SRC KINASE INHIBITING COMPOUNDS |
| GB9919778D0 (en) | 1999-08-21 | 1999-10-27 | Zeneca Ltd | Chemical compounds |
| WO2001025220A1 (en) | 1999-10-07 | 2001-04-12 | Amgen Inc. | Triazine kinase inhibitors |
| ES2254238T3 (en) | 1999-10-27 | 2006-06-16 | Novartis Ag | TIAZOL AND IMIDAZO COMPOUNDS (4,5-B) PIRIDINE AND ITS PHARMACEUTICAL USE. |
| AU3704101A (en) | 2000-02-17 | 2001-08-27 | Amgen Inc | Kinase inhibitors |
| CN100355751C (en) | 2000-03-29 | 2007-12-19 | 西克拉塞尔有限公司 | 2-substd. 4-heteroaryl-pyrimidines and their use in treatment of proliferative disorders |
| MXPA03002299A (en) | 2000-09-15 | 2003-06-06 | Vertex Pharma | Pyrazole compounds useful as protein kinase inhibitors. |
| DE60136731D1 (en) | 2000-09-20 | 2009-01-08 | Ortho Mcneil Pharm Inc | PYRAZINE DERIVATIVES THAN TYROSINE KINASE MODULATORS |
| US6716851B2 (en) | 2000-12-12 | 2004-04-06 | Cytovia, Inc. | Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators or caspases and inducers of apoptosis and the use thereof |
| WO2002047690A1 (en) * | 2000-12-12 | 2002-06-20 | Cytovia, Inc. | Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| WO2002048148A2 (en) | 2000-12-15 | 2002-06-20 | Glaxo Group Limited | Pyrazolopyridine derivatives |
| GB0103926D0 (en) | 2001-02-17 | 2001-04-04 | Astrazeneca Ab | Chemical compounds |
| US7078410B2 (en) | 2001-02-20 | 2006-07-18 | Astrazeneca Ab | 2-arylamino-pyrimidines for the treatment of GSK3-related disorders |
| ES2360205T3 (en) | 2001-03-02 | 2011-06-01 | Agennix Ag | THREE HYBRID TEST SYSTEM. |
| CA2450555A1 (en) | 2001-06-25 | 2003-01-03 | Merck & Co., Inc. | (pyrimidyl)(phenyl)substituted fused heteroaryl p38 inhibiting and pkg kinase inhibiting compounds |
| JP4342937B2 (en) | 2001-07-03 | 2009-10-14 | バーテックス ファーマシューティカルズ インコーポレイテッド | Isoxazole pyrimidines as inhibitors of Src and Lck protein kinases |
| US7109204B2 (en) | 2001-08-01 | 2006-09-19 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| WO2003075828A2 (en) | 2002-03-11 | 2003-09-18 | Zetiq Technologies Ltd. | Compounds useful in the treatment of cancer |
| IL165262A0 (en) | 2002-05-23 | 2005-12-18 | Cytopia Pty Ltd | Kinase inhibitors |
| CA2490907C (en) | 2002-06-28 | 2010-08-24 | Nippon Shinyaku Co., Ltd. | Amide derivative |
| GB0215844D0 (en) | 2002-07-09 | 2002-08-14 | Novartis Ag | Organic compounds |
| US7060850B2 (en) * | 2002-07-11 | 2006-06-13 | Fluorous Technologies Incorporated | Fluorous tagging and scavenging reactants and methods of synthesis and use thereof |
| US20040110821A1 (en) * | 2002-08-07 | 2004-06-10 | Konkel Michael J. | GAL3 receptor antagonists for the treatment of affective disorders |
| UA80296C2 (en) | 2002-09-06 | 2007-09-10 | Biogen Inc | Imidazolopyridines and methods of making and using the same |
| JP2006504755A (en) | 2002-10-15 | 2006-02-09 | スミスクライン ビーチャム コーポレーション | Pyridazine compounds as GSK-3 inhibitors |
| US7169781B2 (en) | 2003-10-17 | 2007-01-30 | Hoffmann-La Roche Inc. | Imidazole derivatives and their use as pharmaceutical agents |
| BRPI0506817A (en) | 2004-01-12 | 2007-05-29 | Cytopia Res Pty Ltd | selective kinase inhibitors |
| EP1713793A4 (en) | 2004-02-04 | 2009-09-02 | Smithkline Beecham Corp | Pyrimidinone compounds useful as kinase inhibitors |
| BRPI0509369B1 (en) * | 2004-03-30 | 2021-08-03 | Vertex Pharmaceuticals Incorporated | AZAINDOIL COMPOUNDS USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES AND PHARMACEUTICAL COMPOSITION |
| JP2006045119A (en) | 2004-08-04 | 2006-02-16 | Toray Ind Inc | Pyrazine derivative and nephritis-treating agent using the same as active ingredient |
| US7855205B2 (en) | 2004-10-29 | 2010-12-21 | Janssen Pharmaceutica Nv | Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders |
| AU2006219231B2 (en) | 2005-02-28 | 2010-01-14 | Japan Tobacco Inc. | Novel aminopyridine compound with Syk inhibitory activity |
| BRPI0609022A2 (en) | 2005-03-10 | 2010-01-12 | Bayer Pharmaceuticals Corp | pyrimidine derivatives for treatment of hyperproliferative disorders |
| JP2009541268A (en) | 2006-06-22 | 2009-11-26 | ビオヴィトルム・アクチボラゲット（プブリクト） | Pyridine and pyrazine derivatives as MNK kinase inhibitors |
| JP2010505794A (en) * | 2006-10-03 | 2010-02-25 | ノイロサーチ アクティーゼルスカブ | Indazolyl derivatives useful as potassium channel modulators |
| CN101516873A (en) * | 2006-10-03 | 2009-08-26 | 神经研究公司 | Indazolyl derivatives useful as potassium channel modulating agents |
| WO2008051494A1 (en) * | 2006-10-19 | 2008-05-02 | Signal Pharmaceuticals, Llc | Heteroaryl compounds, compositions thereof, and use thereof as protein kinase inhibitors |
| US20100048597A1 (en) | 2006-12-22 | 2010-02-25 | Novartis Ag | Organic Compounds and Their Uses |
| PE20081636A1 (en) | 2007-01-26 | 2009-01-10 | Smithkline Beecham Corp | ANTHRANILAMIDE INHIBITORS FOR AURORA KINASE |
| CA2676715A1 (en) | 2007-02-12 | 2008-08-21 | Merck & Co., Inc. | Piperazine derivatives for treatment of ad and related conditions |
| TW200846344A (en) | 2007-04-25 | 2008-12-01 | Astrazeneca Ab | Chemical compounds |
| GB0714573D0 (en) | 2007-07-26 | 2007-09-05 | Imp Innovations Ltd | Marker gene |
| US8415358B2 (en) | 2007-09-17 | 2013-04-09 | Neurosearch A/S | Pyrazine derivatives and their use as potassium channel modulators |
| EA020777B1 (en) | 2007-11-16 | 2015-01-30 | Инсайт Корпорейшн | 4-pyrazolyl-n-arylpyrimidin-2-amines, 4-pyrazolyl-n-pyrazolylpyrimidin-2-amines and 4-pyrazolyl-n-pyridylpyrimidin-2-amines as janus kinase inhibitors |
| CN101883764B (en) | 2007-12-07 | 2013-11-13 | 诺华股份有限公司 | Pyrazole derivatives and use thereof as inhibitors of cyclin dependent kinases |
| DE102008005493A1 (en) | 2008-01-22 | 2009-07-23 | Merck Patent Gmbh | 4- (Pyrrolo [2,3-c] pyridines-3-yl) -pyrimidin-2-yl-amine derivatives |
| GB0801416D0 (en) | 2008-01-25 | 2008-03-05 | Piramed Ltd | Pharmaceutical compounds |
| AU2009238590A1 (en) | 2008-04-22 | 2009-10-29 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
| WO2010002985A1 (en) | 2008-07-01 | 2010-01-07 | Ptc Therapeutics, Inc. | Bmi-1 protein expression modulators |
| EP2328890B1 (en) | 2008-08-06 | 2012-01-25 | Pfizer Inc. | 6 substituted 2-heterocyclylamino pyrazine compounds as chk-1 inhibitors |
| CN102177154A (en) * | 2008-09-02 | 2011-09-07 | 神经研究公司 | Pyrazolyl-pyrimidine derivatives and their use as potassium channel modulators |
| TW201028399A (en) * | 2008-11-27 | 2010-08-01 | Shionogi & Co | Pyrimidine derivative and pyridine derivative both having pi3k inhibitory activity |
| CA2755935A1 (en) | 2009-02-12 | 2010-08-19 | Astellas Pharma Inc. | Hetero ring derivative |
| EP2411387B1 (en) | 2009-03-27 | 2015-08-19 | VetDC, Inc. | Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy |
| CA2763624A1 (en) | 2009-05-27 | 2010-12-02 | Abbott Laboratories | Pyrimidine inhibitors of kinase activity |
| TW201102387A (en) | 2009-06-08 | 2011-01-16 | Medicinova Inc | Substituted pyrazolo[1,5-a]pyridine compounds having multi-target activity |
| DK3141252T3 (en) * | 2009-06-17 | 2018-11-19 | Vertex Pharma | INHIBITORS OF INFLUENZA VIRUS REPLICATION |
| EP3072890B1 (en) | 2009-07-07 | 2018-10-17 | MEI Pharma, Inc. | Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy |
| MX2012000709A (en) | 2009-07-15 | 2012-03-16 | Abbott Lab | Pyrrolopyridine inhibitors of kinases. |
| CN102471345A (en) | 2009-07-15 | 2012-05-23 | 雅培制药有限公司 | Pyrrolopyrazine inhibitors of kinases |
| JP2011136925A (en) * | 2009-12-28 | 2011-07-14 | Dainippon Sumitomo Pharma Co Ltd | Nitrogen-containing bicyclic compound |
| KR101750125B1 (en) | 2010-01-12 | 2017-06-22 | 에이비 사이언스 | Thiazole and oxazole kinase inhibitors |
| UY33213A (en) * | 2010-02-18 | 2011-09-30 | Almirall Sa | PIRAZOL DERIVATIVES AS JAK INHIBITORS |
| ES2365960B1 (en) * | 2010-03-31 | 2012-06-04 | Palobiofarma, S.L | NEW ANTAGONISTS OF ADENOSINE RECEPTORS. |
| ES2580837T3 (en) * | 2010-08-19 | 2016-08-29 | F. Hoffmann-La Roche Ag | Transformation of somatic cells in induced reprogrammed neuronal stem cells (IRNSCS) |
| MX2013002864A (en) | 2010-09-13 | 2013-08-29 | Novartis Ag | Triazine-oxadiazoles. |
| WO2012050884A2 (en) * | 2010-09-28 | 2012-04-19 | President And Fellows Of Harvard College | Cardiac glycosides are potent inhibitors of interferon-beta gene expression |
| CA2819373A1 (en) | 2010-12-09 | 2012-06-14 | Amgen Inc. | Bicyclic compounds as pim inhibitors |
| JP5890436B2 (en) | 2011-02-25 | 2016-03-22 | ユーハン・コーポレイションＹＵＨＡＮ Ｃｏｒｐｏｒａｔｉｏｎ | Diaminopyrimidine derivative and method for producing the same |
| JP6116554B2 (en) | 2011-07-07 | 2017-04-19 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | Substituted azaheterocycles for the treatment of cancer |
| US9695228B2 (en) | 2012-11-21 | 2017-07-04 | Janssen Biotech, Inc. | EGFR and c-Met fibronectin type III domain binding molecules |
| UY35148A (en) | 2012-11-21 | 2014-05-30 | Amgen Inc | HETERODIMERIC IMMUNOGLOBULINS |
| TWI623531B (en) | 2012-11-21 | 2018-05-11 | Ｐｔｃ治療公司 | Substituted reverse pyrimidine bmi-1 inhibitors |
| AU2014235209B2 (en) | 2013-03-15 | 2018-06-14 | Bausch Health Ireland Limited | Guanylate cyclase receptor agonists combined with other drugs |
-
2013
- 2013-11-21 TW TW102142555A patent/TWI623531B/en active
- 2013-11-21 KR KR1020227002513A patent/KR102455889B1/en active IP Right Grant
- 2013-11-21 KR KR1020217020963A patent/KR102356487B1/en active IP Right Grant
- 2013-11-21 AU AU2013348009A patent/AU2013348009C1/en active Active
- 2013-11-21 EA EA201890142A patent/EA035349B1/en not_active IP Right Cessation
- 2013-11-21 PT PT138573266T patent/PT2922828T/en unknown
- 2013-11-21 AR ARP130104300A patent/AR093579A1/en active IP Right Grant
- 2013-11-21 PL PL13857326T patent/PL2922828T3/en unknown
- 2013-11-21 KR KR1020157016184A patent/KR102275676B1/en active IP Right Grant
- 2013-11-21 CU CU2015000053A patent/CU24387B1/en unknown
- 2013-11-21 PE PE2015000665A patent/PE20151413A1/en unknown
- 2013-11-21 DK DK13857326.6T patent/DK2922828T3/en active
- 2013-11-21 NZ NZ70890913A patent/NZ708909A/en unknown
- 2013-11-21 EA EA201590992A patent/EA031405B1/en unknown
- 2013-11-21 BR BR112015011760-0A patent/BR112015011760B1/en active IP Right Grant
- 2013-11-21 MA MA38208A patent/MA38208B1/en unknown
- 2013-11-21 KR KR1020227035587A patent/KR20220143164A/en not_active IP Right Cessation
- 2013-11-21 UA UAA201505533A patent/UA118094C2/en unknown
- 2013-11-21 MX MX2015006469A patent/MX2015006469A/en unknown
- 2013-11-21 ES ES13857326T patent/ES2821529T3/en active Active
- 2013-11-21 CA CA2892045A patent/CA2892045C/en active Active
- 2013-11-21 EP EP13857326.6A patent/EP2922828B1/en active Active
- 2013-11-21 NZ NZ74660713A patent/NZ746607A/en unknown
- 2013-11-21 SG SG10201600149VA patent/SG10201600149VA/en unknown
- 2013-11-21 WO PCT/US2013/071132 patent/WO2014081906A2/en active Application Filing
- 2013-11-21 CN CN201380070973.6A patent/CN104918919A/en active Pending
- 2013-11-21 SG SG11201503982XA patent/SG11201503982XA/en unknown
- 2013-11-21 US US14/443,911 patent/US10428050B2/en active Active
- 2013-11-21 JP JP2015544124A patent/JP6412503B2/en active Active
- 2013-11-21 CN CN202010080540.0A patent/CN111423417B/en active Active
-
2015
- 2015-05-18 IL IL238871A patent/IL238871B/en active IP Right Grant
- 2015-05-20 CL CL2015001377A patent/CL2015001377A1/en unknown
- 2015-05-21 MX MX2021009892A patent/MX2021009892A/en unknown
- 2015-05-21 PH PH12015501130A patent/PH12015501130A1/en unknown
- 2015-05-21 EC ECIEPI201519948A patent/ECSP15019948A/en unknown
- 2015-05-21 SA SA517381847A patent/SA517381847B1/en unknown
- 2015-05-21 NI NI201500072A patent/NI201500072A/en unknown
- 2015-05-22 ZA ZA2015/03642A patent/ZA201503642B/en unknown
- 2015-06-05 CR CR20150294A patent/CR20150294A/en unknown
-
2016
- 2016-03-16 HK HK16103069.2A patent/HK1215032A1/en unknown
-
2018
- 2018-09-28 JP JP2018183173A patent/JP6617186B2/en active Active
-
2019
- 2019-03-10 IL IL265253A patent/IL265253A/en unknown
- 2019-09-26 US US16/583,442 patent/US11180483B2/en active Active
- 2019-11-11 JP JP2019203706A patent/JP6918898B2/en active Active
-
2021
- 2021-11-10 US US17/523,480 patent/US20220064150A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL265253A (en) | Substituted reverse pyrimidine bmi-1 inhibitors | |
| HK1244004A1 (en) | Lactam kinase inhibitors | |
| HK1226057A1 (en) | Substituted pyrimidine bmi-1 inhibitors | |
| HK1210775A1 (en) | Imidazotriazinecarbonitriles useful as kinase inhibitors | |
| ZA201504200B (en) | Beta-lactamase inhibitors | |
| HK1208442A1 (en) | Substituted pyrrolopyrimidinylamino-benzothiazolones as mknk kinase inhibitors mknk | |
| RS63503B1 (en) | Rho kinase inhibitors | |
| SI2855480T1 (en) | Pteridines as fgfr inhibitors | |
| GB201211310D0 (en) | CSF-1R kinase inhibitors | |
| SG11201500973WA (en) | Amino-quinolines as kinase inhibitors | |
| HK1205106A1 (en) | Substituted pyrimidine compounds and their use as syk inhibitors syk | |
| EP2903970A4 (en) | Substituted pyrimidinyl kinase inhibitors | |
| HK1209422A1 (en) | Fbxo3 inhibitors fbxo3 | |
| EP2913325A4 (en) | Substituted pyrimidine compound and uses thereof | |
| EP2922823A4 (en) | Pyrimidine pde10 inhibitors |